SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Chiang et al. investigated a novel SGLT2 inhibitor’s, NGI001, effect on non-alcoholic fatty liver disease (NAFLD) and obesity-associated metabolic symptoms in high-fat diet-induced obese mice.